| 主权项 |
1. A pharmaceutical composition, comprising:
(a) a polypeptide consisting of the following formula I, or a pharmaceutically acceptable salt thereof,[Xaa0]-[Xaa1]-[Xaa2]-[Xaa3]-[Xaa4]-[Xaa5]-[Xaa6]-[Xaa7]-[Xaa8]-[Xaa9]-[Xaa10]-[Xaa11]-[Xaa12]-[Xaa13]-[Xaa14]-[Xaa15]-[Xaa16]-[Xaa17]-[Xaa18]-[Xaa19]-[Xaa20]-[Xaa21]-[Xaa22]-[Xaa23]-[Xaa24]-[Xaa25]-[Xaa26]-[Xaa27]-[Xaa28] (I) wherein, Xaa0 is selected from Lys, Glu, Pro-Ile-Lys, and Ile-Lys; Xaa1 is selected from the group consisting of Thr and Ser; Xaa2 is selected from the group consisting of Ala, Val, Leu and Ile; Xaa3 is selected from the group consisting of Asn, Gln, His, Lys or Arg; Xaa4 is selected from the group consisting of Val, Ile, Leu, Met, Phe and Ala; Xaa5 is selected from the group consisting of Thr and Ser; Xaa6 is selected from the group consisting of Met, Leu, Phe, and Ile; Xaa7 is selected from the group consisting of Gln and Asn; Xaa8 is selected from the group consisting of Leu, Ile, Val, Met, Ala and Phe; Xaa9 is selected from the group consisting of Leu, Ile, Val, Met, Ala and Phe; Xaa10 is selected from the group consisting of Lys, Arg, Gln and Asn; Xaa11 is selected from the group consisting of Ile, Leu, Val, Met, Ala and Phe; Xaa12 is selected from the group consisting of Arg, Pro, Lys, Gln and Asn; Xaa13 is selected from the group consisting of Ser and Thr; Xaa14 is selected from the group consisting of Gly, Pro, and Ala; Xaa15 is selected from the group consisting of Asp, Glu; Xaa16 is selected from the group consisting of Arg, Lys, Gln and Asn; Xaa17 is selected from the group consisting of Pro and Ala; Xaa18 is selected from the group consisting of Ser and Thr; Xaa19 is selected from the group consisting of Tyr, Trp, Phe, Thr and Ser; Xaa20 is selected from the group consisting of Val, Ile, Leu, Met, Phe and Ala; Xaa21 is selected from the group consisting of Glu and Arg; Xaa22 is selected from the group consisting of Leu and Ser; Xaa23 is selected from the group consisting of Thr and Arg; Xaa24 is selected from the group consisting of Phe and Ser; Xaa25 is selected from the group consisting of Ser and Arg; Xaa26 is selected from the group consisting of Gln and Ser; Xaa27 is selected from the group consisting of His and Arg; Xaa28 is absent, or a peptide segment consisting of 1-3 amino acids; and said polypeptide exhibits an activity of inhibiting angiogenesis; and (b) a pharmaceutically acceptable carrier or excipient, wherein the polypeptide is present in an amount effective for treating a disease associated with angiogenesis, and wherein the amount is 10μ to 100 mg. |
